Arrowhead is leveraging RNAi technology acquired from Roche in 2011 to develop a new therapy for hepatitis B.
This RNA therapeutics powerhouse should provide some insightful updates as it enters a critical point in its growth.
RNAi is a new biotech technology investors need to watch.
Allergan (NYSE: AGN) is up versus the S&P 500 in 2014 -- especially since its results were released in early February. Here's why that is.
Seattle Genetics (SGEN) successful Hodgkin's lymphoma drug Adcetris has an opportunity for significant growth if ongoing trials succeed.
These stocks had a great 2013 and may have an even better 2014.
Amgen, Inc.'s (NASDAQ: AMGN) recent results were generally in line with expectations but still should be of major interest to investors.
The healthcare sector is off to another strong start in 2014. The question is whether this strength is the result of irrational exuberance among investors, or improving fundamentals. I dig into this issue over the course of two articles by recapping the highlights of the earnings season in healthcare so far.
Only if investors continue to accept risk.
Amgen's evolocumab looks good so far and has a lead on Regeneron Pharmaceuticals, Sanofi, Alnylam, and the rest of the companies developing PCSK9 inhibitors.